Chinese biotech firms face fresh headwinds in their global expansion as Washington’s proposed outbound investment restrictions threaten to disrupt deal structures, even though drug licensing agreements remain untouched for now, analysts say. The US Treasury Department’s draft rules released last week would “make it much harder for Chinese biotech firms to attract direct US investment or enter joint ventures”, according to David Zhang, an analyst at policy research firm Trivium China. US Treasury...
UPVOTERS
Community appreciation
See who found this content valuable and showed their support.
No upvotes yet.
Be the first to show your appreciation for this content.
TOPICS
Explore the same topics
Discover more content from the topics this post is mapped to.
Keep browsing
Explore more from this topic
Dive into the full feed of curated posts covering Automotive News & Trends.
Discussion
Leave the first comment
Be the first to leave a mark on this discussion.